BARCELONA, Spain, Nov. 4, 2022 /PRNewswire/ -- Werfen announced today that it has agreed to acquire Immucor, Inc., from TPG. Immucor is a private corporation with a strong global presence in in vitro transfusion and transplant diagnostics, headquartered in Norcross, Georgia, USA. This acquisition will enable Werfen to expand its portfolio of specialty diagnostic solutions for hospitals and clinical laboratories.
The purchase price is expected to be approximately US$2 billion, with closing subject to customary regulatory approvals. The acquisition is being financed with a combination of available cash and new senior lines of credit. The company does not expect the transaction to affect its investment grade rating from Standard.
"As a world leader in the research, development, manufacturing and distribution of innovative specialty diagnostic solutions for hospitals and clinical laboratories, Immucor is a natural fit with our existing business model," said Marc Rubiralta, President of Werfen. "We highly value Immucor's commitment to improving care for all patients in need of a transfusion or transplant. This fits perfectly with our long-term vision and strategy, aligns with our approach and complements Werfen's values."
Rubiralta added, "I am confident that by combining two leading complementary companies of Specialized Diagnostics, Werfen will expand its global footprint with further diversification, while successfully maintaining its focus on specialization."
"Immucor's experience and innovations in transfusion and transplant diagnostics allow us to enter new markets and will help achieve our vision of being the preferred choice of the most advanced point-of-care and laboratory customers globally," said Carlos Pascual, CEO of Werfen. "It will be an important milestone in Werfen's future."
Avi Pelossof, CEO of Immucor, said: "As we look to the future, we are excited to increase our impact as part of Werfen, a company that shares our long-term vision and commitment to advancing patient care. globally. As the value of diagnostics grows in the healthcare system, we are confident that Immucor will continue to innovate and succeed under Werfen's ownership."
Once this acquisition is complete, and based on 2021 figures, Werfen will exceed €2.2 billion in revenue, with seven technology centers, nearly 7,000 employees worldwide and a direct presence in 30 countries and more than 100 territories. through distributors.
Werfen was advised by Barclays and Milbank LLP. BBVA, BNP Paribas, CaixaBank and HSBC Holding plc provided commitments for the new senior credit facilities. Sellers and Immucor were advised by Evercore and Ropes
Throw
Founded in 1966, Werfen is a global developer, manufacturer and distributor of specialty diagnostic instruments, related reagents, automation work cells and data management solutions for use primarily in hospitals and independent clinical laboratories. The company's business units include hemostasis, acute care diagnostics, autoimmunity, and original equipment manufacturing (OEM). Werfen operates directly in almost 30 countries and in more than 100 territories through distributors. For more information visit www.werfen.com
TPG
TPG is a leading global alternative asset management company, founded in San Francisco in 1992, with $127 billion in assets under management and investment and operating teams in 12 offices worldwide. TPG invests across five multi-product platforms: Equity, Growth, Impact, Real Estate and Market Solutions, and our unique strategy is driven by collaboration, innovation and inclusion. Our teams combine deep product and industry experience with broad capabilities and knowledge to develop differentiated perspectives and add value for our fund investors, portfolio companies, management teams and communities. For more information, visit www.tpg.com or @TPG on Twitter.
Legal note
This document contains forward-looking statements about our business, financial data and events related to Werfen's prospects. These forecasts can be identified by the use of words such as "expectation", "vision", "anticipation", "intent", "plan", "belief", "search", "estimate", "future", "project". ", or words with a similar meaning. We may also make projections in other reports, presentations and press releases. In addition, our sales representatives may from time to time make forward-looking statements. These projections are based on our current expectations and certain assumptions, many of which are beyond the control of the corporation and are subject to a number of risks and uncertainties.In the event that any of these risks or uncertainties materialize or underlying expectations are not met, Werfen's results or performance may differ materially (either positively or negatively) from those expressly or impliedly anticipated Werfen undertakes no obligation to update or revise any forward-looking statements made previously.
Photo - linkLogo - link
View original content: enlace
